Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.
about
Shining a light on intestinal trafficMyelin recovery in multiple sclerosis: the challenge of remyelinationMechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients."Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.Fingolimod for relapsing multiple sclerosis: an update.Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytesPharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.An emerging role for the lipid mediator sphingosine-1-phosphate in mast cell effector function and allergic disease.FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value.A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.Novel therapies in transplantation.Development and Effects of FTY720 Ophthalmic Solution on Corneal Allograft SurvivalFTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphomaThe S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment.FTY720 (fingolimod) in renal transplantation.Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.Current perspectives on FTY720.Fingolimod: a novel immunosuppressant for multiple sclerosis.FTY720 (fingolimod) for relapsing multiple sclerosis.Vascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammationSignaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis.Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.A Chemoattractant-Guided Walk Through Lymphopoiesis: From Hematopoietic Stem Cells to Mature B Lymphocytes.FTY720 reduces inflammation and promotes functional recovery after spinal cord injury.Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort.Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.Gastric parietal cell atrophy and depletion after administration of a sphingosine-1-phosphate 1 inhibitor.Population pharmacokinetics of fingolimod phosphate in healthy participants.A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator.FTY720 pharmacokinetics in mild to moderate hepatic impairment.The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo.Differential effects of fingolimod on B-cell populations in multiple sclerosis.
P2860
Q26863227-9015AEAB-C386-4A85-A847-75848D858D84Q33772195-E67C13A4-8EF5-4066-A019-22151702E422Q33881977-310355E6-1691-4ED8-B628-346E903AFFEFQ34421642-CB90293C-AB9F-4ABA-8D11-60D120EA2250Q34593159-6941F5B4-BAC1-467C-9231-FD06621ED124Q34618474-33DA9DD8-03E3-4DA4-8F1E-D823BABA6D4DQ35107430-81B782DE-E554-453F-A911-96C43106F12BQ35130512-F94C627C-111A-425C-84AD-4C4D55324ED0Q35545433-F78407D4-996A-4EF2-8BDC-0587E6EDBD92Q35876398-CAFF86D2-1B56-42F3-B9D6-B3BB4AA4E1B7Q35953902-0D8368DD-68E5-4015-896E-EE22A2CBC1ACQ36099424-359E7F7A-3651-4DE6-8A41-C1D51F243FBFQ36272747-AE91A3B8-3ED4-4DF4-A7FE-07C8FC8BAA61Q36384629-91069C36-4F31-4D2B-B78F-BFBC2666D7B5Q36473213-49DBF489-5A0C-441E-9EFA-AFF1D59112D6Q36652022-E0D587AF-C65A-42FF-80C3-18BD7CACBF0BQ36652104-F1916AD4-2B72-493B-A507-25505A2FA678Q36764024-7D9A9BA7-A916-4056-AF3A-84B1EFC53B00Q36929186-5D6D549E-7457-4CA4-919B-4CC753962F47Q37154788-A527D40E-01BE-4479-908E-647393573F09Q37293908-866BEE04-2697-4B09-91EE-256EA63FA352Q37997376-6270D364-4F65-4854-A93D-0164B0894560Q38005193-3227545F-3A27-401E-B6F0-AAC817D962B4Q38606914-39A52620-ECC4-443C-83FD-2428A3F8DC18Q39245050-A1614141-0906-4C53-BEAD-61EE544CA539Q39918468-C029958A-5D7D-4EDB-B360-DFC96328C241Q42655958-2217E218-8937-4BFA-A9BC-07263134B0EBQ42759772-8434338C-2008-405F-A60D-525E618B2DA5Q44811888-923E724F-CEA2-4EFB-94EC-B576BDAE92A5Q45171971-232BBCF3-7E5E-47CA-86FF-5E2C4DD68EEFQ45183765-9C358EFB-09C6-4795-9073-CD8232D4F0E9Q46210843-21D9FDC8-1C9B-4E24-98B5-BC872E6FA163Q46391230-6ABF3223-E6E1-4F3A-9FF3-72670AA45833Q46741854-55A62FCD-4F80-4A29-815F-4B495FBFB5D9Q50860736-492D64E4-840E-44AE-8C04-CA34201C662A
P2860
Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Pharmacodynamics of single dos ...... ble renal transplant patients.
@en
Pharmacodynamics of single dos ...... ble renal transplant patients.
@nl
type
label
Pharmacodynamics of single dos ...... ble renal transplant patients.
@en
Pharmacodynamics of single dos ...... ble renal transplant patients.
@nl
prefLabel
Pharmacodynamics of single dos ...... ble renal transplant patients.
@en
Pharmacodynamics of single dos ...... ble renal transplant patients.
@nl
P2093
P2860
P1476
Pharmacodynamics of single dos ...... able renal transplant patients
@en
P2093
Andrej Skerjanec
Bjorn Nashan
Hans-Hellmut Neumayer
Jerry Nedelman
Laurence Brookman
Peter W Lücker
Reinhard Brunkhorst
Robert L Schmouder
Thomas Mayer
Torsten Böhler
P2860
P304
P356
10.1034/J.1600-6143.2003.00130.X
P407
P577
2003-07-01T00:00:00Z